Chengdu Novo Suntai Biotechnology

Chengdu Nuoshengtai Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the development of innovative peptide therapeutics for metabolic and endocrine disorders. The company focuses on multi-receptor agonists, particularly targeting GLP-1, GIP, and Glucagon receptors to treat conditions such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Its lead candidate, NST-001, is a long-acting tri-agonist designed to provide superior weight loss and glycemic control compared to existing mono- or dual-agonists. Nuoshengtai leverages its proprietary peptide engineering platform to optimize the pharmacokinetic profiles and therapeutic efficacy of its pipeline candidates. The company is a key player in the emerging metabolic disease therapeutic space within the Chengdu Tianfu International Bio-town cluster.